Asthma - Epidemiology Forecast - 2034

Key Highlights

• The analyst projects that among the total diagnosed prevalent cases of asthma in 7MM approximately 47% of cases were from the US in 2022. The increase in asthma cases is likely due to a combination of genetic predisposition, environmental factors like air pollution and allergens, changes in lifestyle, and improved awareness and diagnosis.
• In 2022, the adult population constituted 80% of total diagnosed asthma cases across the 7MM, reflecting the greater prevalence of asthma among adults due to factors such as prolonged exposure to environmental triggers and untreated childhood asthma persisting into adulthood.
• The projection that severity-specific intermittent asthma cases will surpass other categories by 2034 suggests a potential trend towards improved asthma management and prevention strategies, leading to fewer severe cases. This underscores the importance of early detection and targeted interventions to mitigate disease progression and reduce healthcare burden.
• As asthma prevalence evolves, understanding emerging environmental and genetic factors alongside advancements in medical interventions will be pivotal in shaping future prevalence rates and guiding effective prevention and management strategies.

The “Asthma - Epidemiology Forecast - 2034” report delivers an in-depth understanding of the asthma, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2020-2034

Disease Understanding and Treatment Algorithm

Asthma Overview

Asthma, a prevalent non-communicable disease (NCD), impacts individuals across all age groups, with children being particularly vulnerable as it stands as the most common chronic condition among them. The manifestation of asthma symptoms, including coughing, wheezing, shortness of breath, and chest tightness, results from inflammation and narrowing of the small airways in the lungs. Additionally, avoiding triggers associated with asthma can further alleviate symptoms.

The burden of asthma-related deaths predominantly falls on low- and lower-middle-income countries, where challenges like under-diagnosis and under-treatment persist. The World Health Organization (WHO) is dedicated to enhancing asthma diagnosis, treatment, and monitoring to alleviate the global NCD burden and progress towards achieving universal health coverage.

Asthma Diagnosis

Diagnosing asthma involves gathering a comprehensive medical history, conducting a physical examination, and performing lung function tests like spirometry. While these methods aid in identifying characteristic symptoms and airflow obstruction, challenges such as variability in symptoms and overlap with other conditions can complicate diagnosis. Additionally, limitations in access to healthcare and diagnostic resources may contribute to under-diagnosis, particularly in marginalized communities. Efforts to improve asthma diagnosis include refining diagnostic criteria, enhancing access to testing, and promoting awareness among healthcare providers.

Asthma Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the Total Diagnosed Prevalent Cases of Asthma, Age-specific Diagnosed Prevalent Cases of Asthma, Gender-specific Diagnosed Prevalent Cases of Asthma, Severity-specific Diagnosed Prevalent Cases of Asthma, and Type-specific Diagnosed Prevalent Cases of Severe Asthma in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034.

As per the estimations, the total diagnosed prevalent cases of Asthma in the 7MM were around 54 million in 2022 and are projected to increase during the forecast period (2023-2034).

• There were approximately 26 million diagnosed prevalent cases of Asthma estimated to have occurred in the US in 2022. These cases are anticipated to grow in the foreseeable future during the study period.
• In 2022, EU4 and the UK accounted for nearly 25 million diagnosed prevalent population of asthma, projected to increase at a significant CAGR by 2034. Among EU4 and the UK, the UK accounted for the highest number of diagnosed asthma cases in 2022.
• Age-specific diagnosed prevalent cases of Asthma is categorized into pediatric and adults, with 5 million and about 20 million cases respectively in the US in 2022.
• The categorization based on gender, showed that diagnosed prevalent cases in female was higher than that in males. The female diagnosed prevalent cases accounted for 56% of the total cases in 2022.
• In the Japan, the intermittent, mild, moderate, and severe cases of asthma were over 2 million, 0.5 million, 0.8 million, and 0.6 million cases, respectively, in 2022.
• Type-specific diagnosed prevalent cases of Severe Asthma was segmented into type-2 inflammation and non-type-2 inflammation, among which the type-2 inflammation has a higher prevalence in 2022.

KOL Views

To gaze into the epidemiology insights of the real world, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate the secondary research. Industry Experts were contacted for insights on asthma evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, along with challenges related to accessibility, including KOL from University of Michigan, US; Cincinnati Children’s Hospital Medical Center, US; Pulmonary Department, Mainz University Hospital, Mainz, Germany; Department of Pharmacology, University Hospital Agostino Gemelli Foundation, Rome, Italy; Department of Respiratory Medicine, Queen Mary University of London, UK; Department of Respiratory Medicine and Clinical Immunology, Osaka University, Japan; and others.

The analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps understand and validate current disease prevalence, gender involved with the disease, diagnosis rate, and diagnostic criteria.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Asthma, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, and guidelines.
• The report provides an edge for understanding trends, expert insights/KOL views, and patient journeys in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Asthma Report Insights

• Twelve Years Forecast of Asthma
• The 7MM Coverage
• Total Diagnosed Prevalent Cases Of Asthma
• Age-Specific Diagnosed Prevalent Cases Of Asthma
• Gender-Specific Diagnosed Prevalent Cases Of Asthma
• Severity-Specific Diagnosed Prevalent Cases Of Asthma
• Type-Specific Diagnosed Prevalent Cases Of Severe Asthma

Asthma Report Key Strengths

• 12 years Forecast
• The 7MM Coverage
• Asthma Epidemiology Segmentation

Key Questions

Epidemiology Insights

• What are the disease risks and burdens of Asthma?
• What is the historical Asthma patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• What would be the forecasted patient pool of Asthma at the 7MM level?
• What growth opportunities will be across the 7MM concerning the patient population with Asthma?
• Which country would have the highest diagnosed prevalent population of Asthma among the countries mentioned above, during the forecast period (2023-2034)?
• At what CAGR is the population expected to grow across the 7MM during the forecast period (2023-2034)?

Reasons to Buy

The Asthma report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the 7MM Asthma epidemiology forecast.
• The Asthma epidemiology report and model were written and developed by Master’s and PhD-level epidemiologists.
• The Asthma epidemiology model developed by the publisher is easy to navigate, interactive with a dashboard, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports the data presented in the report and showcases disease trends over the 12-year forecast period using reputable sources.

Frequently Asked Questions

1. What is the forecast period covered in the report?

The Asthma Epidemiology report for the 7MM covers the forecast period from 2023 to 2034, providing a projection of epidemiology dynamics and trends during this timeframe.

2. Out of all EU4 countries and the UK, which country had the highest population of Asthma cases in 2023?
The highest cases of Asthma was found in the UK among the European Countries in 2022.

3. How is epidemiological data collected and analyzed for forecasting purposes?

Epidemiological data is collected through surveys, clinical studies, health records, and other sources. It is then analyzed to calculate disease rates, identify trends, and project future disease burdens using mathematical models.

4. Out of all 7MM countries, which country had the highest population of Asthma cases in 2022?

The highest cases of Asthma were found in the US among the 7MM in 2022.